vasopermeation enhancement

vasopermeation enhancement

Oncology An investigational therapy that ↑ up to 3-fold CA cell uptake of chemotherapeutics
References in periodicals archive ?
Peregrine Pharmaceuticals is also developing Vascular Targeting Agents, Anti-Angiogenesis, and Vasopermeation Enhancement Agents (VEAs) for the treatment of cancer and other diseases.
Peregrine Pharmaceuticals (Tustin, CA) announced the issuance of United States Patent 6,696,276 that covers its Vasopermeation Enhancement Agent (VEA) technology.
Peregrine's Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA) technologies target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types.
6007817 for Techniclone's Vasopermeation Enhancement Agent ("VEA") technology.
Our agents in development for oncology applications fall under several different proprietary platforms, including Anti-Phospholipid Therapy, Vascular Targeting Agents (VTAs), Tumor Necrosis Therapy (TNT), Anti-Angiogenesis, and Vasopermeation Enhancement Agents (VEAs).
The company is also developing two additional technologies for the treatment of solid tumors, Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA).
Peregrine's Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA) target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types.
Technology Will be Employed to Advance Peregrine's Vasopermeation Enhancement Agent (VEA) Technology Toward Clinical Trials
The PEP technology has been exclusively licensed to Peregrine and is part of its Vasopermeation Enhancement Agents (VEA) technology platform which is used to enhance existing cancer therapeutic and diagnostic agents.
Peregrine's Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA) technologies target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types.
6,403,096 covering the use of Permeability Enhancing Peptide (PEP) as a Vasopermeation Enhancement Agent (VEA).
The PEP technology is part of a class of compounds called Vasopermeation Enhancement Agents (VEA) being developed by Peregrine.